Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors
University of California, San Francisco
University of California, San Francisco
Memorial Sloan Kettering Cancer Center
Imperial College London
City of Hope Medical Center
University of Michigan Rogel Cancer Center
Rutgers, The State University of New Jersey
UMC Utrecht
Aveni Foundation
National Taiwan University Hospital
Dana-Farber Cancer Institute
Duke University
Essen Biotech
Azienda Ospedaliero-Universitaria di Parma
Unity Health Toronto
City of Hope Medical Center
University of Nebraska
HealthPartners Institute
OHSU Knight Cancer Institute
City of Hope Medical Center
Mayo Clinic
Cancer Research UK
Dana-Farber Cancer Institute
UNC Lineberger Comprehensive Cancer Center
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
Maastricht University Medical Center
Institut Bergonié
Washington University School of Medicine
Jonsson Comprehensive Cancer Center
Jonsson Comprehensive Cancer Center
Cancer Research UK
Cancer Research UK
Columbia University
Abramson Cancer Center at Penn Medicine
Royal Marsden NHS Foundation Trust
Stanford University
Cedars-Sinai Medical Center
Centre Georges Francois Leclerc
University Health Network, Toronto
Stanford University
Universidade Federal de Pernambuco
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Mayo Clinic
Stanford University
University of Sydney
Second Affiliated Hospital of Guangzhou Medical University
Washington University School of Medicine
Cedars-Sinai Medical Center
Beijing Friendship Hospital
Peking University Third Hospital